Second generation cephalosporins enhanced activity against Escherichia coli, Klebsiella spp., and Proteus mirabilis. In addition, they have greater activity in vitro against a larger number of gram-negative bacteria, including Haemophilus influenzae, indole-positive Proteus, Neiserria meningitidis, N. gonorrheae and some strains of Serratia and Enterobacter spp.
Cefuroxime is the only second-generation cephalosporin to adequately penetrate into the cerebral spinal fluid (CSF).
Cefuroxime is used in the treatment of septicemia, bone and joint infections, gram-negative pneumonia, skin and soft tissue infections, including burn wound infections, and urinary tract infections caused by susceptible bacterial organisms.
Cefuroxime is commonly used to treat community-acquired pneumonias because of its activity against S. pneumoniae, S.aureus and H. influenzae. Also to treat meningitis caused by S. pneumoniae, H. influenzae and N. meningitidis.
Other Services
Country
Account